- Conditions
- Pain
- Interventions
- VX-708, Itraconazole, Midazolam, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 7,030
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Long QT Syndrome
- Interventions
- GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Healthy
- Interventions
- Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 2
- States / cities
- Saint Charles, Missouri • Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- SB-756050 immediate release capsule, SB-756050 modified release capsule, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Healthy, Late Onset Pompe Disease
- Interventions
- ABX1100 injection for IV infusion, Placebo injection for IV infusion
- Drug
- Lead sponsor
- Aro Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • St Louis, Missouri • Fairfax, Virginia
- Conditions
- Healthy Volunteers
- Interventions
- DNL201, Placebo
- Drug
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy
- Interventions
- LY4355756, Midazolam
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obesity, Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3, Duragesic 25 mcg/h + Clinical Procedure 1, Duragesic 25 mcg/h + Clinical Procedure 2, Duragesic 25 mcg/h + Clinical Procedure 3
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Depressive Disorder, Major
- Interventions
- LY2216684, Activated Charcoal
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV Infected Population With Latent Tuberculosis
- Interventions
- rifapentene (RPT), darunavir/cobicistat (DRV/c), Isoniazid (INH), Pyridoxine
- Drug · Dietary Supplement
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- TS-134, Placebo, Ketamine
- Drug · Other
- Lead sponsor
- Taisho Pharmaceutical R&D Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Adult Volunteers
- Interventions
- Drug: OP0201, Drug: Placebo
- Combination Product
- Lead sponsor
- Novus Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Tolerance
- Interventions
- 1 serving of test product, 2 servings of test product, 3 servings of test product, Placebo
- Other
- Lead sponsor
- Liquid I.V.
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Hyperalgesia
- Interventions
- Alfentanil, Diphenhydramine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- PF 06260414 solid dose formulation, PF-06260414 nanosuspension
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- Nitrous oxide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 21 Years to 37 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1995 – 1996
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy
- Interventions
- BPM31510 Oral Nanosuspension 4%
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Focus of the Study: Safety of XFB19
- Interventions
- XFB19, Placebo
- Drug
- Lead sponsor
- Xfibra, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Healthy
- Interventions
- SKI-606
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Safety and Tolerability
- Interventions
- YJ001 for Spray Use, Placebo of YJ001 for Spray Use
- Drug
- Lead sponsor
- Yuejia Pharmaceuticals (USA), Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Overweight, Eating Behavior, Binge Eating
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Drug Safety
- Interventions
- MDT-637
- Drug
- Lead sponsor
- MicroDose Therapeutx, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Hypoglycemia
- Interventions
- G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas